155 related articles for article (PubMed ID: 16715412)
21. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.
Kandeel M; Al-Nazawi M
Life Sci; 2020 Jun; 251():117627. PubMed ID: 32251634
[TBL] [Abstract][Full Text] [Related]
22. In silico prediction of SARS protease inhibitors by virtual high throughput screening.
Plewczynski D; Hoffmann M; von Grotthuss M; Ginalski K; Rychewski L
Chem Biol Drug Des; 2007 Apr; 69(4):269-79. PubMed ID: 17461975
[TBL] [Abstract][Full Text] [Related]
23. Application of bioinformatics in search for cleavable peptides of SARS-CoV M(pro) and chemical modification of octapeptides.
Du Q; Wang S; Jiang Z; Gao W; Li Y; Wei D; Chou KC
Med Chem; 2005 May; 1(3):209-13. PubMed ID: 16787316
[TBL] [Abstract][Full Text] [Related]
24. Interaction of small molecules with the SARS-CoV-2 main protease in silico and in vitro validation of potential lead compounds using an enzyme-linked immunosorbent assay.
Pitsillou E; Liang J; Karagiannis C; Ververis K; Darmawan KK; Ng K; Hung A; Karagiannis TC
Comput Biol Chem; 2020 Dec; 89():107408. PubMed ID: 33137690
[TBL] [Abstract][Full Text] [Related]
25. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
26. Discovery of inhibitors against SARS-CoV-2 main protease using fragment-based drug design.
Shao HP; Wang TH; Zhai HL; Bi KX; Zhao BQ
Chem Biol Interact; 2023 Feb; 371():110352. PubMed ID: 36642317
[TBL] [Abstract][Full Text] [Related]
27. Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design.
Xu X; Liu Y; Weiss S; Arnold E; Sarafianos SG; Ding J
Nucleic Acids Res; 2003 Dec; 31(24):7117-30. PubMed ID: 14654687
[TBL] [Abstract][Full Text] [Related]
28. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK
Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348
[TBL] [Abstract][Full Text] [Related]
29. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
30. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.
Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S
Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074
[TBL] [Abstract][Full Text] [Related]
31. Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin.
Kwofie SK; Broni E; Asiedu SO; Kwarko GB; Dankwa B; Enninful KS; Tiburu EK; Wilson MD
Molecules; 2021 Jan; 26(2):. PubMed ID: 33466743
[TBL] [Abstract][Full Text] [Related]
32. The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase.
Lung J; Lin YS; Yang YH; Chou YL; Shu LH; Cheng YC; Liu HT; Wu CY
J Med Virol; 2020 Jun; 92(6):693-697. PubMed ID: 32167173
[TBL] [Abstract][Full Text] [Related]
33. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
[TBL] [Abstract][Full Text] [Related]
34. Identifying inhibitors of the SARS coronavirus proteinase.
Jenwitheesuk E; Samudrala R
Bioorg Med Chem Lett; 2003 Nov; 13(22):3989-92. PubMed ID: 14592491
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 and SARS-CoV: Virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12).
Ruan Z; Liu C; Guo Y; He Z; Huang X; Jia X; Yang T
J Med Virol; 2021 Jan; 93(1):389-400. PubMed ID: 32579254
[TBL] [Abstract][Full Text] [Related]
36. A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an in silico investigation.
Rakib A; Nain Z; Sami SA; Mahmud S; Islam A; Ahmed S; Siddiqui ABF; Babu SMOF; Hossain P; Shahriar A; Nainu F; Emran TB; Simal-Gandara J
Brief Bioinform; 2021 Mar; 22(2):1476-1498. PubMed ID: 33623995
[TBL] [Abstract][Full Text] [Related]
37. Generation of predictive pharmacophore model for SARS-coronavirus main proteinase.
Zhang XW; Yap YL; Altmeyer RM
Eur J Med Chem; 2005 Jan; 40(1):57-62. PubMed ID: 15642409
[TBL] [Abstract][Full Text] [Related]
38. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
Cetin A
Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
[TBL] [Abstract][Full Text] [Related]
39. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
[TBL] [Abstract][Full Text] [Related]
40. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
